UFF
CRSP icon

USA Financial Formulas’s CRISPR Therapeutics CRSP Stock Holding History

USA Financial Formulas’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,921
Closed -$348K – 330
2018
Q3 		$348K Buy
+5,921
New +$310K 0.09% 195

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

USA Financial Formulas's CRSP Position: Q4 2018 in Review

USA Financial Formulas sold out of CRISPR Therapeutics (CRSP) in Q4 2018, closing a stake of 5,921 shares — an estimated $348K sold.

USA Financial Formulas first reported a position in CRSP in Q3 2018 and held it in 1 quarter. The position peaked at $348K in Q3 2018. 155 funds tracked by Wall St. Rank hold CRSP as of Q4 2018.

  • USA Financial Formulas reported no remaining CRISPR Therapeutics position as of Q4 2018 after selling out during the quarter.
  • USA Financial Formulas sold 5,921 CRISPR Therapeutics shares in Q4 2018, an estimated $348K.
  • USA Financial Formulas first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 1 quarter.
  • USA Financial Formulas's CRISPR Therapeutics position peaked at $348K in Q3 2018.
  • 155 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2018.

Based on USA Financial Formulas's 13F filing for Q4 2018, filed 14 Feb 2019.